Literature DB >> 3998828

Current application of "high-dose" steroid therapy for CNS injury. A pharmacological perspective.

J M Braughler, E D Hall.   

Abstract

Although administration of glucocorticoid steroids is one of the most widely used therapeutic modalities for the clinical management of acute trauma of the central nervous system (CNS), controversy continues regarding their effectiveness. In essence, two viewpoints concerning their use exist. Some believe that despite their poor clinical record, the steroids nevertheless have a place in the treatment of human CNS trauma. In general, this group of clinical investigators uses the steroids primarily out of tradition, feeling that steroid therapy may be of some benefit. Unfortunately, confusion remains as to what constitutes an appropriate dose or regimen. In this regard, it has been suggested that the steroid dose be increased and the regimen intensified. Others believe that steroids should not be used. They contend that in view of their poor clinical record, it is unlikely that increasing the steroid dose or changing the dosing regimen will improve clinical efficacy, since steroids have already failed at what may be considered huge doses by glucocorticoid standards. Furthermore, it is contended that the side effects associated with large steroid doses reduce the margin of safety so as to make the steroids unsafe. Complicating these arguments is a body of experimental evidence that by and large strongly supports the utility of steroids for the acute treatment of CNS trauma. The intent of this article is to evaluate the current use of steroid therapy for CNS trauma from a purely pharmacological perspective, and to compare the steroids' experimental use with their clinical application.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3998828     DOI: 10.3171/jns.1985.62.6.0806

Source DB:  PubMed          Journal:  J Neurosurg        ISSN: 0022-3085            Impact factor:   5.115


  15 in total

1.  Evaluation of the neuroprotective effects of citicoline after experimental spinal cord injury: improved behavioral and neuroanatomical recovery.

Authors:  Neslihan Yücel; Süleyman R Cayli; Ozkan Ateş; Neşe Karadağ; Serpil Firat; Yusuf Turköz
Journal:  Neurochem Res       Date:  2006-06-21       Impact factor: 3.996

2.  Cortisol promotes survival and regeneration of axotomised retinal ganglion cells and enhances effects of aurintricarboxylic acid.

Authors:  Peter Heiduschka; Solon Thanos
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  2006-03-28       Impact factor: 3.117

3.  The antioxidant effect of beta-Glucan on oxidative stress status in experimental spinal cord injury in rats.

Authors:  Hakan Kayali; M Fatih Ozdag; Serdar Kahraman; Ahmet Aydin; Engin Gonul; Ahmet Sayal; Zeki Odabasi; Erdener Timurkaynak
Journal:  Neurosurg Rev       Date:  2005-04-30       Impact factor: 3.042

Review 4.  Patterns of cervical spine injury and their associated lesions.

Authors:  A N Guthkelch; A S Fleischer
Journal:  West J Med       Date:  1987-10

5.  The MRC CRASH Trial: study design, baseline data, and outcome in 1000 randomised patients in the pilot phase.

Authors:  P Edwards; B Farrell; G Lomas; R Mashru; N Ritchie; I Roberts; P Sandercock; J Wasserberg; D Yates
Journal:  Emerg Med J       Date:  2002-11       Impact factor: 2.740

6.  Methylprednisolone therapy in laser injury of the retina.

Authors:  T T Lam; K Takahashi; J Fu; M O Tso
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1993-12       Impact factor: 3.117

7.  [Clinical experiences and results of high-dosage methylprednisolone therapy in spinal cord trauma 1991 to 1993].

Authors:  C Gäbler; R Maier
Journal:  Unfallchirurgie       Date:  1995-02

8.  Retinal toxicity of intravitreal lazaroid (21-aminosteroid U75412E).

Authors:  S A Cruz; M Karaçorlu; G A Peyman
Journal:  Int Ophthalmol       Date:  1992-05       Impact factor: 2.031

Review 9.  Head trauma in the child.

Authors:  R C Pascucci
Journal:  Intensive Care Med       Date:  1988       Impact factor: 17.440

10.  Corticosteroids inhibit the generation of lymphokine-activated killer activity in vitro.

Authors:  D W McVicar; R E Merchant; L H Merchant; H F Young
Journal:  Cancer Immunol Immunother       Date:  1989       Impact factor: 6.968

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.